US biotechnology giant Gilead Sciences announced Monday generic licensing deals with seven Indian pharmaceutical firms to slash the cost of its $1,000-a-pill Hepatitis C medicine in 91 developing countries. Gilead has come under fire from patient rights' groups for the cost of its Hepatitis C drug, Sovaldi, which in the US costs $84,000 for a total 12-week course of treatment. "This announcement is a game-changer," Greg Alton, Gilead medical affairs executive vice-president, told AFP in New Delhi where the announcement was made. Gilead said the seven Indian firms to which it has licensed its Hepatitis C drug include Cipla, Ranbaxy Laboratories, Cadila Healthcare and Mylan Laboratories.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment